{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:54:43Z","timestamp":1792698883603,"version":"4.5.0"},"reference-count":91,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.2018.0345","type":"journal-article","created":{"date-parts":[[2018,5,16]],"date-time":"2018-05-16T12:18:21Z","timestamp":1526473101000},"source":"Crossref","is-referenced-by-count":38,"title":["Treatment Options for Carbapenem-Resistant Gram-Negative Infections"],"prefix":"10.3238","author":[{"given":"Moritz","family":"Fritzenwanker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Imirzalioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Herold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian M.","family":"Wagenlehner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus-Peter","family":"Zimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trinad","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2018,5,21]]},"reference":[{"key":"10.3238\/arztebl.2018.0345_ref1","unstructured":"Robert Koch-Institut: ARS (Antibiotika Resistenz Surveillance). https:\/\/ars.rki.de (last accessed on 6 April 2018)."},{"key":"10.3238\/arztebl.2018.0345_ref2","doi-asserted-by":"crossref","unstructured":"Kommission f\u00fcr Krankenhaushygiene und Infektionspr\u00e4vention (KRINKO) beim Robert Koch-Institut (RKI): Hygienema\u00dfnahmen bei Infektionen oder Besiedlung mit multiresistenten gramnegativen St\u00e4bchen. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2012; 55: 1311\u201354","DOI":"10.1007\/s00103-012-1549-5"},{"key":"10.3238\/arztebl.2018.0345_ref3","unstructured":"Robert Koch-Institut: Zur aktuellen Situation bei Carbapenemase-bildenden gramnegativen Bakterien. Epidemiologisches Bulletin 2013; 19; 167\u201371."},{"key":"10.3238\/arztebl.2018.0345_ref4","doi-asserted-by":"crossref","unstructured":"Magiorakos AP, Burns K, Rodr\u00edguez Ba\u00f1o J, et al.: Infection prevention and control measures and tools for the prevention of entry of carbapenem-resistant Enterobacteriaceae into healthcare settings: guidance from the European Centre for Disease Prevention and Control. Antimicrob Resist Infect Control 2017; 6: 113","DOI":"10.1186\/s13756-017-0259-z"},{"key":"10.3238\/arztebl.2018.0345_ref5","doi-asserted-by":"crossref","unstructured":"Bassetti M, Peghin M, Pecori D: The management of multidrug-resistant Enterobacteriaceae. Curr Opin Infect Dis 2016; 29: 583\u201394","DOI":"10.1097\/QCO.0000000000000314"},{"key":"10.3238\/arztebl.2018.0345_ref6","doi-asserted-by":"crossref","unstructured":"Satlin MJ, Kubin CJ, Blumenthal JS, et al.: Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine. Antimicrob Agents Chemother 2011; 55: 5893\u20139","DOI":"10.1128\/AAC.00387-11"},{"key":"10.3238\/arztebl.2018.0345_ref7","doi-asserted-by":"crossref","unstructured":"Temkin E, Torre-Cisneros J, Beovic B, et al.: Ceftazidime-avibactam as salvage therapy for infections caused by Carbapenem-resistant organisms. Antimicrob Agents Chemother 2017; 61: e01964\u201316","DOI":"10.1128\/AAC.01964-16"},{"key":"10.3238\/arztebl.2018.0345_ref8","doi-asserted-by":"crossref","unstructured":"Shields RK, Potoski BA, Haidar G, et al.: Clinical outcomes, drug toxicity, and emergence of Ceftazidime-avibactam resistance among patients treated for Carbapenem-resistant Enterobacteriaceae infections. Clin Infect Dis 2016; 63: 1615\u20138","DOI":"10.1093\/cid\/ciw636"},{"key":"10.3238\/arztebl.2018.0345_ref9","doi-asserted-by":"crossref","unstructured":"Wu G, Abraham T, Lee S: Ceftazidime-Avibactam for treatment of Carbapenem-resistant Enterobacteriaceae Bacteremia. Clin Infect Dis 2016; 63: 1147\u20138","DOI":"10.1093\/cid\/ciw491"},{"key":"10.3238\/arztebl.2018.0345_ref10","doi-asserted-by":"crossref","unstructured":"Shields RK, Nguyen MH, Chen L, et al.: Ceftazidime-Avibactam is superior to other treatment regimens against Carbapenem-resistant Klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother 2017; 61: e00883\u201317","DOI":"10.1128\/AAC.00883-17"},{"key":"10.3238\/arztebl.2018.0345_ref11","doi-asserted-by":"crossref","unstructured":"King M, Heil E, Kuriakose S, et al.: Multicenter study of outcomes with Ceftazidime-Avibactam in patients with Carbapenem-resistant Enterobacteriaceae infections. Antimicrob Agents Chemother 2017; 61: e00449\u201317","DOI":"10.1128\/AAC.00449-17"},{"key":"10.3238\/arztebl.2018.0345_ref12","doi-asserted-by":"crossref","unstructured":"Krapp F, Grant JL, Sutton SH, Ozer EA, Barr VO: Treating complicated carbapenem-resistant enterobacteriaceae infections with ceftazidime\/avibactam: a retrospective study with molecular strain characterisation. Int J Antimicrob Agents 2017; 49: 770\u20133","DOI":"10.1016\/j.ijantimicag.2017.01.018"},{"key":"10.3238\/arztebl.2018.0345_ref13","doi-asserted-by":"crossref","unstructured":"Munita JM, Aitken SL, Miller WR, et al.: Multicenter evaluation of Ceftolozane\/Tazobactam for serious infections caused by Carbapenem-resistant Pseudomonas aeruginosa. Clin Infect Dis 2017; 65: 158\u201361","DOI":"10.1093\/cid\/cix014"},{"key":"10.3238\/arztebl.2018.0345_ref14","doi-asserted-by":"crossref","unstructured":"Xiao AJ, Caro L, Popejoy MW, et al.: PK\/PD target attainment with Ceftolozane\/Tazobactam using Monte Carlo simulation in patients with various degrees of renal function, including augmented renal clearance and end-stage renal disease. Infect Dis Ther 2017; 6: 137\u201348","DOI":"10.1007\/s40121-016-0143-9"},{"key":"10.3238\/arztebl.2018.0345_ref15","doi-asserted-by":"crossref","unstructured":"Xiao AJ, Miller BW, Huntington JA, Nicolau DP: Ceftolozane\/tazobactam pharmacokinetic\/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia. J Clin Pharmacol 2016; 56: 56\u201366","DOI":"10.1002\/jcph.566"},{"key":"10.3238\/arztebl.2018.0345_ref16","doi-asserted-by":"crossref","unstructured":"Ozbek B, Mataracı-Kara E, Er S, Ozdamar M, Yilmaz M: In vitro activities of colistin, tigecycline and tobramycin, alone or in combination, against carbapenem-resistant Enterobacteriaceae strains. J Glob Antimicrob Resist 2015; 3: 278\u201382","DOI":"10.1016\/j.jgar.2015.09.001"},{"key":"10.3238\/arztebl.2018.0345_ref17","doi-asserted-by":"crossref","unstructured":"Satlin MJ, Chen L, Patel G, et al.: Multicenter clinical and molecular epidemiological analysis of bacteremia due to Carbapenem-resistant Enterobacteriaceae (CRE) in the CRE Epicenter of the United States. Antimicrob Agents Chemother 2017; 61: e02349\u201316","DOI":"10.1128\/AAC.02349-16"},{"key":"10.3238\/arztebl.2018.0345_ref18","doi-asserted-by":"crossref","unstructured":"Guti\u00e9rrez-Guti\u00e9rrez B, Salamanca E, de Cueto M, et al.: Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infect Dis 2017; 17: 726\u201334","DOI":"10.1016\/S1473-3099(17)30522-4"},{"key":"10.3238\/arztebl.2018.0345_ref19","doi-asserted-by":"crossref","unstructured":"Alexander EL, Loutit J, Tumbarello M et al.: Carbapenem-resistant Enterobacteriaceae infections: results from a retrospective series and implications for the design of prospective clinical trials. Open Forum Infect Dis 2017; 4: ofx063","DOI":"10.1093\/ofid\/ofx063"},{"key":"10.3238\/arztebl.2018.0345_ref20","doi-asserted-by":"crossref","unstructured":"Ni W, Han Y, Liu J, et al.: Tigecycline treatment for Carbapenem-resistant Enterobacteriaceae infections: a systematic review and meta-analysis. Medicine 2016; 95: e3126","DOI":"10.1097\/MD.0000000000003126"},{"key":"10.3238\/arztebl.2018.0345_ref21","doi-asserted-by":"crossref","unstructured":"Chen Z, Chen Y, Fang Y, et al.: Meta-analysis of colistin for the treatment of Acinetobacter baumannii infection. Sci Rep 2015; 5: 17091","DOI":"10.1038\/srep17091"},{"key":"10.3238\/arztebl.2018.0345_ref22","doi-asserted-by":"crossref","unstructured":"Zusman O, Altunin S, Koppel F, Dishon Benattar Y, Gedik H, Paul M: Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis. J Antimicrob Chemother 2017; 72: 29\u201339","DOI":"10.1093\/jac\/dkw377"},{"key":"10.3238\/arztebl.2018.0345_ref23","doi-asserted-by":"crossref","unstructured":"Ni W, Cai X, Wei C, et al.: Efficacy of polymyxins in the treatment of carbapenem-resistant Enterobacteriaceae infections: a systematic review and meta-analysis. Brazilian J Infect Dis 2015; 19: 170\u201380","DOI":"10.1016\/j.bjid.2014.12.004"},{"key":"10.3238\/arztebl.2018.0345_ref24","doi-asserted-by":"crossref","unstructured":"Paul M, Carmeli Y, Durante-Mangoni E, et al.: Combination therapy for carbapenem-resistant Gram-negative bacteria. J Antimicrob Chemother 2014; 69: 2305\u20139","DOI":"10.1093\/jac\/dku168"},{"key":"10.3238\/arztebl.2018.0345_ref25","doi-asserted-by":"crossref","unstructured":"Cristina ML, Alicino C, Sartini M, et al.: Epidemiology, management, and outcome of carbapenem-resistant Klebsiella pneumoniae bloodstream infections in hospitals within the same endemic metropolitan area. J Infect Public Health 2018; 11: 171\u20137","DOI":"10.1016\/j.jiph.2017.06.003"},{"key":"10.3238\/arztebl.2018.0345_ref26","doi-asserted-by":"crossref","unstructured":"Cheng A, Chuang YC, Sun HY, et al.: Excess mortality associated with Colistin-Tigecycline compared with Colistin-Carbapenem combination therapy for extensively drug-resistant Acinetobacter baumannii bacteremia. Crit Care Med 2015; 43: 1194\u2013204","DOI":"10.1097\/CCM.0000000000000933"},{"key":"10.3238\/arztebl.2018.0345_ref27","doi-asserted-by":"crossref","unstructured":"Souli M, Karaiskos I, Masgala A, Galani L, Barmpouti E, Giamarellou H: Double-carbapenem combination as salvage therapy for untreatable infections by KPC-2-producing Klebsiella pneumoniae. Eur J Clin Microbiol Infect Dis 2017; 36: 1305\u201315","DOI":"10.1007\/s10096-017-2936-5"},{"key":"10.3238\/arztebl.2018.0345_ref28","doi-asserted-by":"crossref","unstructured":"Cprek JB, Gallagher JC: Ertapenem-containing double-Carbapenem therapy for treatment of infections caused by Carbapenem-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother 2015; 60: 669\u201373","DOI":"10.1128\/AAC.01569-15"},{"key":"10.3238\/arztebl.2018.0345_ref29","doi-asserted-by":"crossref","unstructured":"Oliva A, Gizzi F, Mascellino MT, et al.: Bactericidal and synergistic activity of double-carbapenem regimen for infections caused by carbapenemase-producing Klebsiella pneumoniae. Clin Microbiol Infect 2016; 22: 147\u201353","DOI":"10.1016\/j.cmi.2015.09.014"},{"key":"10.3238\/arztebl.2018.0345_ref30","doi-asserted-by":"crossref","unstructured":"De Pascale G, Martucci G, Montini L, et al.: Double carbapenem as a rescue strategy for the treatment of severe carbapenemase-producing Klebsiella pneumoniae infections: a two-center, matched case-control study. Crit Care 2017; 21: 173","DOI":"10.1186\/s13054-017-1769-z"},{"key":"10.3238\/arztebl.2018.0345_ref31","doi-asserted-by":"crossref","unstructured":"Oliva A, Scorzolini L, Castaldi D, et al.: Double-carbapenem regimen, alone or in combination with colistin, in the treatment of infections caused by carbapenem-resistant Klebsiella pneumoniae (CR-Kp). J Infect 2017; 74: 103\u20136","DOI":"10.1016\/j.jinf.2016.10.002"},{"key":"10.3238\/arztebl.2018.0345_ref32","doi-asserted-by":"crossref","unstructured":"Durante-Mangoni E, Signoriello G, Andini R, et al.: Colistin and Rifampicin compared with Colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis 2013; 57: 349\u201358","DOI":"10.1093\/cid\/cit253"},{"key":"10.3238\/arztebl.2018.0345_ref33","doi-asserted-by":"crossref","unstructured":"Dickstein Y, Leibovici L, Yahav D, et al.: Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol. BMJ Open 2016; 6: e009956","DOI":"10.1136\/bmjopen-2015-009956"},{"key":"10.3238\/arztebl.2018.0345_ref34","unstructured":"Trial for the treatment of extensively drug-resistant gram-negative bacilli. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01597973 (last accessed on 22 November 2017)."},{"key":"10.3238\/arztebl.2018.0345_ref35","doi-asserted-by":"crossref","unstructured":"Bodmann KF, Grabein B, Kresken M, et al.: S2k Leitlinie Kalkulierte parenterale Initialtherapie bakterieller Erkrankungen bei Erwachsenen \u2013 Update 2018. Paul-Ehrlich-Gesellschaft f\u00fcr Chemotherapie e. V. (PEG) 2018. (last accessed on 8 March 2018).","DOI":"10.1055\/s-0043-114874"},{"key":"10.3238\/arztebl.2018.0345_ref36","unstructured":"L\u00fcbbert C: Epidemiologie und Therapie von Infektionen durch Carbapenem-resistente Enterobakterien (CRE) in Deutschland. Arzneiverordnung der Praxis 2016; 43: 80\u201391."},{"key":"10.3238\/arztebl.2018.0345_ref37","doi-asserted-by":"crossref","unstructured":"Drusano GL, Louie A.: Optimization of aminoglycoside therapy. Antimicrob Agents Chemother 201; 55: 2528\u201331","DOI":"10.1128\/AAC.01314-10"},{"key":"10.3238\/arztebl.2018.0345_ref38","doi-asserted-by":"crossref","unstructured":"Florent A, Chichmanian RM, Cua E, Pulcini C: Adverse events associated with intravenous fosfomycin. Int J Antimicrob Agents 2011; 37: 82\u20133","DOI":"10.1016\/j.ijantimicag.2010.09.002"},{"key":"10.3238\/arztebl.2018.0345_ref39","doi-asserted-by":"crossref","unstructured":"Goodlet KJ, Nicolau DP, Nailor MD: Ceftolozane\/tazobactam and ceftazidime\/avibactam for the treatment of complicated intra-abdominal infections. Ther Clin Risk Manag 2016; 12: 1811\u201326","DOI":"10.2147\/TCRM.S120811"},{"key":"10.3238\/arztebl.2018.0345_ref40","doi-asserted-by":"crossref","unstructured":"Morrill HJ, Pogue JM, Kaye KS, LaPlante KL: Treatment options for Carbapenem-resistant enterobacteriaceae infections. Open Forum Infect Dis 2015; 2: ofv050","DOI":"10.1093\/ofid\/ofv050"},{"key":"10.3238\/arztebl.2018.0345_ref41","unstructured":"Siegmund-Schultze N: Spektrum an Problemkeimen w\u00e4chst. Dtsch Arztebl 2016; 113: A-655"},{"key":"10.3238\/arztebl.2018.0345_ref42","doi-asserted-by":"crossref","unstructured":"Maechler F, Geffers C, Schwab F, Pe\u00f1a Diaz LA., Behnke M, Gastmeier P: Entwicklung der Resistenzsituation in Deutschland. Medizinische Klin \u2013 Intensivmed und Notfallmedizin 2017; 112: 186\u201391","DOI":"10.1007\/s00063-017-0272-2"},{"key":"10.3238\/arztebl.2018.0345_ref43","doi-asserted-by":"crossref","unstructured":"Alexander EL, Loutit J, Tumbarello M, et al.: Carbapenem-resistant enterobacteriaceae infections: results from a retrospective series and implications for the design of prospective clinical trials. Open Forum Infect Dis 2017; 4: ofx063.","DOI":"10.1093\/ofid\/ofx063"},{"key":"10.3238\/arztebl.2018.0345_ref44","doi-asserted-by":"crossref","unstructured":"Conly J, Johnston B: Colistin: the phoenix arises. Can J Infect Dis Med Microbiol 2006; 17: 267\u20139","DOI":"10.1155\/2006\/901873"},{"key":"10.3238\/arztebl.2018.0345_ref45","unstructured":"European Committee on Antimicrobial Susceptibility Testing: EUCAST warnings concerning antimicrobial susceptibility testing products or procedures. www.eucast.org\/ast_of_bacteria\/warnings\/ (last accessed on 6 September 2017)."},{"key":"10.3238\/arztebl.2018.0345_ref46","doi-asserted-by":"crossref","unstructured":"Chew KL, La MV, Lin RTP, Teo JWP: Colistin and Polymyxin B susceptibility testing for Carbapenem-resistant and mcr-positive Enterobacteriaceae: comparison of Sensititre, MicroScan, Vitek 2, and Etest with broth microdilution. J Clin Microbiol 2017; 55: 2609\u201316","DOI":"10.1128\/JCM.00268-17"},{"key":"10.3238\/arztebl.2018.0345_ref47","doi-asserted-by":"crossref","unstructured":"Fritzenwanker M, Imirzalioglu C, Gentil K, Falgenhauer L, Wagenlehner FM, Chakraborty T: Incidental detection of a urinary Escherichia coli isolate harbouring mcr-1 of a patient with no history of colistin treatment. Clin Microbiol Infect 2016; 22: 954\u20135","DOI":"10.1016\/j.cmi.2016.08.027"},{"key":"10.3238\/arztebl.2018.0345_ref48","doi-asserted-by":"crossref","unstructured":"McGovern PC, Wible M, El-Tahtawy A, Biswas P, Meyer RD: All-cause mortality imbalance in the tigecycline phase 3 and 4 clinical trials. Int J Antimicrob Agents 2013; 41: 463\u20137","DOI":"10.1016\/j.ijantimicag.2013.01.020"},{"key":"10.3238\/arztebl.2018.0345_ref49","unstructured":"Kombinationstherapie bei Infektionen mit Carbapenem-resistenten Erregern. Zeitschrift f\u00fcr Chemother 2014; 21\u20135."},{"key":"10.3238\/arztebl.2018.0345_ref50","doi-asserted-by":"crossref","unstructured":"Singh RSP, Mukker JK, Drescher SK, Deitchman AN, Derendorf H: A need to revisit clinical breakpoints of tigecycline: effect of atypical non-linear plasma protein binding. Int J Antimicrob Agents 2017; 49: 449\u201355","DOI":"10.1016\/j.ijantimicag.2016.12.008"},{"key":"10.3238\/arztebl.2018.0345_ref51","doi-asserted-by":"crossref","unstructured":"De Pascale G, Montini L, Pennisi M, et al.: High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria. Crit Care 2014; 18: R90.","DOI":"10.1186\/cc13858"},{"key":"10.3238\/arztebl.2018.0345_ref52","doi-asserted-by":"crossref","unstructured":"Ramirez J, Dartois N, Gandjini H, Yan JL, Korth-Bradley J, Mcgovern PC: Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus Imipenem-Cilastatin for treatment of hospital-acquired pneumonia. AAC 2013; 57: 1756\u201362","DOI":"10.1128\/AAC.01232-12"},{"key":"10.3238\/arztebl.2018.0345_ref53","doi-asserted-by":"crossref","unstructured":"Giammanco A, Cal\u00e0 C, Fasciana T, Dowzicky MJ: Global assessment of the activity of Tigecycline against multidrug-resistant gram-negative pathogens between 2004 and 2014 as part of the tigecycline evaluation and surveillance trial. mSphere 2017; 2: e00310\u20136.","DOI":"10.1128\/mSphere.00310-16"},{"key":"10.3238\/arztebl.2018.0345_ref54","doi-asserted-by":"crossref","unstructured":"Pontikis K, Karaiskos I, Bastani S, et al.: Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing gram-negative bacteria. Int J Antimicrob Agents 2014; 4: 52\u20139","DOI":"10.1016\/j.ijantimicag.2013.09.010"},{"key":"10.3238\/arztebl.2018.0345_ref55","doi-asserted-by":"crossref","unstructured":"Grabein B, Graninger W, Rodr\u00edguez Ba\u00f1o J, Dinh A, Liesenfeld DB: Intravenous fosfomycin\u2014back to the future. Systematic review and meta-analysis of the clinical literature. Clin Microbiol Infect 2017; 23: 363\u201372","DOI":"10.1016\/j.cmi.2016.12.005"},{"key":"10.3238\/arztebl.2018.0345_ref56","doi-asserted-by":"crossref","unstructured":"del Rio A, Gasch O, Moreno A, et al.: Efficacy and safety of fosfomycin plus imipenem as rescue therapy for complicated bacteremia and endocarditis due to methicillin-resistant Staphylococcus aureus: a multicenter clinical trial. Clin Infect Dis 2014; 59: 1105\u201312","DOI":"10.1093\/cid\/ciu580"},{"key":"10.3238\/arztebl.2018.0345_ref57","doi-asserted-by":"crossref","unstructured":"Tumbarello M, Trecarichi EM, De Rosa FG, et al.: Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother 2015; 70: 2133\u201343","DOI":"10.1093\/jac\/dkv200"},{"key":"10.3238\/arztebl.2018.0345_ref58","doi-asserted-by":"crossref","unstructured":"Del Bono V, Giacobbe DR, Marchese A, et al.: Meropenem for treating KPC-producing Klebsiella pneumoniae bloodstream infections: should we get to the PK\/PD root of the paradox? Virulence 2017; 8: 66\u201373.","DOI":"10.1080\/21505594.2016.1213476"},{"key":"10.3238\/arztebl.2018.0345_ref59","doi-asserted-by":"crossref","unstructured":"Thaden JT, Pogue JM, Kaye KS: Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae. Virulence 2017; 8: 403\u201316","DOI":"10.1080\/21505594.2016.1207834"},{"key":"10.3238\/arztebl.2018.0345_ref60","doi-asserted-by":"crossref","unstructured":"de Jonge BLM, Karlowsky JA, Kazmierczak KM, Biedenbach DJ, Sahm DF, Nichols WW: In vitro susceptibility to Ceftazidime-Avibactam of Carbapenem-nonsusceptible Enterobacteriaceae isolates collected during the INFORM global surveillance study (2012 to 2014). Antimicrob Agents Chemother 2016; 60: 3163\u20139","DOI":"10.1128\/AAC.03042-15"},{"key":"10.3238\/arztebl.2018.0345_ref61","doi-asserted-by":"crossref","unstructured":"Grupper M, Sutherland C, Nicolau DP: Multicenter evaluation of Ceftazidime-avibactam and Ceftolozane-tazobactam inhibitory activity against Meropenem non-susceptible P. aeruginosa from blood, respiratory tract and wounds. Antimicrob Agents Chemother 2017; 61. pii: e00875\u201317.","DOI":"10.1128\/AAC.00875-17"},{"key":"10.3238\/arztebl.2018.0345_ref62","doi-asserted-by":"crossref","unstructured":"Goodlet KJ, Nicolau DP, Nailor MD: Ceftolozane\/tazobactam and ceftazidime\/avibactam for the treatment of complicated intra-abdominal infections. Ther Clin Risk Manag 2016; 12: 1811\u201326.","DOI":"10.2147\/TCRM.S120811"},{"key":"10.3238\/arztebl.2018.0345_ref63","doi-asserted-by":"crossref","unstructured":"Pfaller MA, Bassetti M, Duncan LR, Castanheira M: Ceftolozane\/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012\u201315). J Antimicrob Chemother 2018; 72: 1386\u201395.","DOI":"10.1093\/jac\/dkx009"},{"key":"10.3238\/arztebl.2018.0345_ref64","doi-asserted-by":"crossref","unstructured":"Kohira N, West J, Ito A, et al.: In vitro antimicrobial activity of a Siderophore Cephalosporin, S-649266, against Enterobacteriaceae clinical isolates, including Carbapenem-resistant strains. Antimicrob Agents Chemother 2016; 60: 729\u201334","DOI":"10.1128\/AAC.01695-15"},{"key":"10.3238\/arztebl.2018.0345_ref65","doi-asserted-by":"crossref","unstructured":"Ito A, Nishikawa T, Matsumoto S, et al.: Siderophore Cephalosporin Cefiderocol utilizes ferric iron transporter systems for antibacterial activity against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2016; 60: 7396\u2013401.","DOI":"10.1128\/AAC.01405-16"},{"key":"10.3238\/arztebl.2018.0345_ref66","doi-asserted-by":"crossref","unstructured":"Ito-Horiyama T, Ishii Y, Ito A, et al.: Stability of novel siderophore Cephalosporin S-649266 against clinically relevant Carbapenemases. Antimicrob Agents Chemother 2016; 60: 4384\u20136","DOI":"10.1128\/AAC.03098-15"},{"key":"10.3238\/arztebl.2018.0345_ref67","doi-asserted-by":"crossref","unstructured":"Andreeva E, Melbye H: Usefulness of C-reactive protein testing in acute cough\/respiratory tract infection: an open cluster-randomized clinical trial with C-reactive protein testing in the intervention group. BMC Fam Pract 2014; 15: 80","DOI":"10.1186\/1471-2296-15-80"},{"key":"10.3238\/arztebl.2018.0345_ref68","doi-asserted-by":"crossref","unstructured":"Wagenlehner FM, Alidjanov JF: Efficacy, pharmacokinetic and pharmacodynamic profile of ceftolozane + tazobactam in the treatment of complicated urinary tract infections. Expert Opin Drug Metab Toxicol 2016; 12: 959\u201366","DOI":"10.1080\/17425255.2016.1201065"},{"key":"10.3238\/arztebl.2018.0345_ref69","doi-asserted-by":"crossref","unstructured":"Wagenlehner FM, Umeh O, Steenbergen J, Yuan G, Darouiche RO: Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet 2015; 385: 1949\u201356","DOI":"10.1016\/S0140-6736(14)62220-0"},{"key":"10.3238\/arztebl.2018.0345_ref70","doi-asserted-by":"crossref","unstructured":"Solomkin J, Hershberger E, Miller B, et al.: Ceftolozane\/Tazobactam plus Metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI). Clin Infect Dis 2015; 60: 1462\u201371","DOI":"10.1093\/cid\/civ097"},{"key":"10.3238\/arztebl.2018.0345_ref71","doi-asserted-by":"crossref","unstructured":"Wagenlehner FM, Sobel JD, Newell P, et al.: Ceftazidime-avibactam versus Doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program. Clin Infect Dis 2016; 63: 754\u201362","DOI":"10.1093\/cid\/ciw378"},{"key":"10.3238\/arztebl.2018.0345_ref72","doi-asserted-by":"crossref","unstructured":"Mazuski JE, Gasink LB, Armstrong J, et al.: Efficacy and safety of Ceftazidime-Avibactam plus Metronidazole versus Meropenem in the treatment of complicated intra-abdominal infection: Results from a randomized,controlled, double-blind, phase 3 program. Clin Infect Dis 2016; 62: 1380\u20139","DOI":"10.1093\/cid\/ciw133"},{"key":"10.3238\/arztebl.2018.0345_ref73","doi-asserted-by":"crossref","unstructured":"Carmeli Y, Armstrong J, Laud PJ, et al.: Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis 2016; 16: 661\u201373","DOI":"10.1016\/S1473-3099(16)30004-4"},{"key":"10.3238\/arztebl.2018.0345_ref74","unstructured":"ClinicalTrials.gov: Comparative study of coadministered Ceftaroline Fosamil and NXL104 vs. Intravenous Doripenem in adult subjects with complicated urinary tract infections. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01281462?term=ceftaroline+avibactam&rank=2 (last accessed on 24 January 2017)."},{"key":"10.3238\/arztebl.2018.0345_ref75","unstructured":"ClinicalTrials.gov: Determine the PK and safety and tolerability of ATM-AVI for the treatment of cIAIs in hospitalized adults. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02655419?term=aztreonam+avibactam&rank=2 (last accessed on 24 January 2017)."},{"key":"10.3238\/arztebl.2018.0345_ref76","unstructured":"ClinicalTrials.gov: Efficacy, safety, tolerability of Carbavance compared to Piperacillin\/Tazobactam in complicated urinary tract infections (cUTIs), including acute pyelonephritis (AP), in adults. www.clinicaltrials.gov\/ct2\/show\/NCT02166476?term=meropenem+vaborbactam&rank=2 (last accessed on 24 January 2017)."},{"key":"10.3238\/arztebl.2018.0345_ref77","doi-asserted-by":"crossref","unstructured":"Castanheira M, Rhomberg PR, Flamm RK, Jones RN: Effect of the β-Lactamase inhibitor Vaborbactam combined with Meropenem against serine Carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2016; 60: 5454\u20138","DOI":"10.1128\/AAC.00711-16"},{"key":"10.3238\/arztebl.2018.0345_ref78","doi-asserted-by":"crossref","unstructured":"Lapuebla A, Abdallah M, Olafisoye O, et al.: Activity of Meropenem combined with RPX7009, a novel β-Lactamase inhibitor, against gram-negative clinical isolates in New York City. Antimicrob Agents Chemother 2015; 59: 4856\u201360","DOI":"10.1128\/AAC.00843-15"},{"key":"10.3238\/arztebl.2018.0345_ref79","doi-asserted-by":"crossref","unstructured":"Lucasti C, Vasile L, Sandesc D, et al.: Phase 2, dose-ranging study of Relebactam with Imipenem-Cilastatin in subjects with complicated intra-abdominal infection. Antimicrob Agents Chemother 2016; 60: 6234\u201343","DOI":"10.1128\/AAC.00633-16"},{"key":"10.3238\/arztebl.2018.0345_ref80","doi-asserted-by":"crossref","unstructured":"Abdallah M, Olafisoye O, Cortes C, Urban C, Landman D, Quale J: Activity of Eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City. Antimicrob Agents Chemother 2015; 59: 1802\u20135","DOI":"10.1128\/AAC.04809-14"},{"key":"10.3238\/arztebl.2018.0345_ref81","doi-asserted-by":"crossref","unstructured":"Solomkin J, Evans D, Slepavicius A, et al.: Assessing the efficacy and safety of Eravacycline vs Ertapenem in complicated intraabdominal infections in the Investigating Gram-Negative Infections Treated with Eravacycline (IGNITE 1) Trial. JAMA Surg 2017; 152: 224\u201332","DOI":"10.1001\/jamasurg.2016.4237"},{"key":"10.3238\/arztebl.2018.0345_ref82","doi-asserted-by":"crossref","unstructured":"Kocsis B, Domokos J, Szabo D: Chemical structure and pharmacokinetics of novel quinolone agents represented by Avarofloxacin, Delafloxacin, Finafloxacin, Zabofloxacin and Nemonoxacin. Ann Clin Microbiol Antimicrob 2016; 15: 34","DOI":"10.1186\/s12941-016-0150-4"},{"key":"10.3238\/arztebl.2018.0345_ref83","doi-asserted-by":"crossref","unstructured":"Wagenlehner FME, Wagenlehner CM, Blenk B, et al.: Urinary pharmacokinetics and bactericidal activity of Finafloxacin (200 and 800 mg) in healthy volunteers receiving a single oral dose. Chemotherapy 2011; 57: 97\u2013107","DOI":"10.1159\/000321028"},{"key":"10.3238\/arztebl.2018.0345_ref84","unstructured":"ClinicalTrials.gov: Finafloxacin for the treatment of cUTI and\/or acute pyelonephritis. www.clinicaltrials.gov\/ct2\/show\/NCT01928433?term=finafloxacin&rank=7 (last accessed on 24\u00a0January 2017)."},{"key":"10.3238\/arztebl.2018.0345_ref85","unstructured":"ClinicalTrials.gov: Search of: delafloxacin. www.clinicaltrials.gov\/ct2\/results?term=delafloxacin&Search=Search (last accessed on 24\u00a0January 2017)."},{"key":"10.3238\/arztebl.2018.0345_ref86","unstructured":"ClinicalTrials.gov: Search of: zabofloxacin. www.clinicaltrials.gov\/ct2\/results?term=zabofloxacin&Search=Search (last accessed on 24 January 2017)."},{"key":"10.3238\/arztebl.2018.0345_ref87","unstructured":"ClinicalTrials.gov: Search of: nemonoxacin. www.clinicaltrials.gov\/ct2\/results?term=nemonoxacin&Search=Search (last accessed on 24 January 2017)."},{"key":"10.3238\/arztebl.2018.0345_ref88","doi-asserted-by":"crossref","unstructured":"Walkty A, Adam H, Baxter M, et al.: In vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in Canadian hospitals as part of the CANWARD study, 2011\u20132012. Antimicrob Agents Chemother; 58: 2554\u201363.","DOI":"10.1128\/AAC.02744-13"},{"key":"10.3238\/arztebl.2018.0345_ref89","unstructured":"ClinicalTrials.gov: Search of: plazomicin. www.clinicaltrials.gov\/ct2\/results?term=plazomicin&Search=Search (last accessed on 24\u00a0January 2017)."},{"key":"10.3238\/arztebl.2018.0345_ref90","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez-Avial I, Pena I, Picazo JJ, Rodr\u00edguez-Avial C, Culebras E: In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae strains. Int J Antimicrob Agents; 46: 616\u201321.","DOI":"10.1016\/j.ijantimicag.2015.07.021"},{"key":"10.3238\/arztebl.2018.0345_ref91","unstructured":"Gilbert DN, Chambers HF, Eliopoulos GM, et al. (eds.): The Sanford guide to antimicrobial therapy. 2017."}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2018.0345","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T13:40:43Z","timestamp":1638798043000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2018.0345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,21]]},"references-count":91,"URL":"https:\/\/doi.org\/10.3238\/arztebl.2018.0345","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,21]]}}}